Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

2021184 citationsJournal Articlegold Open Access

Authors

ClinicalTrials.gov identifier: NCT02734160.

Good health and well-being

Published in: Journal for ImmunoTherapy of Cancer

Volume 9, Issue 3, pp. e002068-e002068

Field-Weighted Citation Impact: 11.62